Expansion of immunotherapy PBS listing to treat multiple new cancers (Australian Government Department of Health) - Aug 30, 2026 - "From September 1, Pembrolizumab (Keytruda) is being significantly expanded as a multi-cancer listing for Australians living with advanced and high-risk cancers....Keytruda has already been listed on the PBS for 17 cancer indications, now clinicians will have the option of prescribing the treatment for additional advanced cancers including: Advanced cholangiocarcinoma (Bile duct cancer); Ovarian cancer; Merkel cell carcinoma (a rare skin cancer)....Separately, Keytruda has also been newly listed in combination with the drug Enfortumab Vedotin (Padcev) for the treatment of patients with Stage 3 or 4 urothelial cancer."
Reimbursement • Biliary Tract Cancer • Cholangiocarcinoma • Merkel Cell Carcinoma • Ovarian Cancer • Urothelial Cancer
|